How to Get Prescribed Ozempic for Weight Loss: The Exact Clinical Criteria and Documentation Providers Require

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Ozempic is FDA-approved only for type 2 diabetes, but providers can prescribe it off-label for weight loss if you meet BMI thresholds (30+ or 27+ with comorbidities) and have documented failed attempts at diet and exercise
• Insurance rarely covers Ozempic for weight loss without diabetes, but will often cover Wegovy (same active ingredient, different indication), though prior authorization requires 3-6 months of documented weight management attempts
• The prescription pathway differs dramatically between traditional in-person providers (who prioritize insurance coverage and require extensive documentation) and telehealth platforms (who prescribe compounded semaglutide at lower cost but without insurance)
• The single most common denial reason is insufficient documentation of prior weight loss attempts, not BMI or medical necessity

Direct answer (40-60 words)

To get prescribed Ozempic for weight loss, you need a BMI of 30 or higher (or 27+ with weight-related conditions like hypertension or prediabetes), documentation of failed diet and exercise attempts over 3 to 6 months, and a provider willing to prescribe off-label. Insurance coverage requires meeting Wegovy's FDA-approved criteria and prior authorization.

Table of contents

1. The FDA approval gap: why Ozempic isn't technically a weight-loss drug
2. The clinical criteria providers actually use
3. The documentation you need before your appointment
4. The three prescription pathways: traditional, telehealth, and compounded
5. What most articles get wrong about insurance coverage
6. The prior authorization process for Wegovy vs off-label Ozempic
7. When providers say no: the four common denial patterns
8. The cost comparison: brand Ozempic vs Wegovy vs compounded semaglutide
9. The FormBlends prescription decision tree
10. State-by-state telehealth prescribing restrictions
11. FAQ
12. Footer disclaimers

The FDA approval gap: why Ozempic isn't technically a weight-loss drug

Ozempic (semaglutide 0.5 mg, 1 mg, 2 mg) received FDA approval in 2017 for type 2 diabetes management, not weight loss. The approval was based on the SUSTAIN clinical trial series, which measured A1C reduction as the primary endpoint. Weight loss was a documented secondary outcome (patients lost an average of 12.4 pounds over 56 weeks in SUSTAIN-1), but the drug was not studied or approved specifically for obesity treatment (Sorli et al., Lancet Diabetes & Endocrinology 2017).

Wegovy (semaglutide 2.4 mg) is the same molecule at a higher dose, approved in 2021 specifically for chronic weight management based on the STEP trial program. The STEP-1 trial showed 14.9% average body weight reduction over 68 weeks in patients without diabetes (Wilding et al., New England Journal of Medicine 2021).

The practical result: providers can legally prescribe Ozempic off-label for weight loss under their clinical judgment, but insurance companies almost never cover it for that indication because an FDA-approved alternative (Wegovy) exists for the same purpose.

This creates the central tension in the prescription pathway. If you want insurance coverage, you need to qualify for and obtain Wegovy, not Ozempic. If you're paying out of pocket or using a telehealth platform, the distinction becomes less relevant because you're accessing the same active ingredient through different channels.

The clinical criteria providers actually use

Providers follow evidence-based guidelines when prescribing GLP-1 receptor agonists for weight management, regardless of whether they write for brand-name Ozempic, Wegovy, or compounded semaglutide. The criteria come from the 2022 American Gastroenterological Association Clinical Practice Update on obesity pharmacotherapy (Grunvald et al., Gastroenterology 2022).

Primary qualifying criteria:

• BMI ≥ 30 kg/m², or
• BMI ≥ 27 kg/m² with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease, nonalcoholic fatty liver disease, or polycystic ovary syndrome)
• Age 18 or older (pediatric use of Wegovy was approved in 2022 for ages 12+, but Ozempic remains adult-only)

Secondary clinical considerations:

• Documented attempts at lifestyle modification (diet and exercise) for at least 3 to 6 months without achieving 5% body weight reduction
• No contraindications: personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, history of pancreatitis, severe gastroparesis, pregnancy or planned pregnancy within 2 months
• No active eating disorder diagnosis
• Willingness to participate in ongoing lifestyle modification during treatment

The 3-to-6-month lifestyle modification documentation requirement is the most variable. Traditional providers often require formal documentation (dietitian visits, food logs, exercise records). Telehealth platforms typically accept patient attestation. Insurance companies always require formal documentation for prior authorization.

The documentation you need before your appointment

The difference between getting prescribed on the first visit versus being told to "try diet and exercise for 6 months and come back" is usually documentation. Providers need to justify the prescription in your medical record, especially if insurance is involved.

Bring or be prepared to discuss:

1. Weight history. Documented weights over the past 6 to 12 months showing stable obesity or weight gain despite efforts. If you've been seeing a primary care provider, request weight records from past visits.

1. Prior weight loss attempts. Specific programs, duration, and outcomes. Examples: "Tried Weight Watchers for 4 months in 2024, lost 8 pounds, regained 12 pounds within 6 months" or "Worked with a dietitian for 3 months, followed 1,500-calorie meal plan, lost 5 pounds, plateaued."

1. Comorbidity documentation. If your BMI is 27 to 29.9, you need documented evidence of a qualifying condition. Bring recent lab results showing elevated A1C (prediabetes), lipid panel (dyslipidemia), or blood pressure readings (hypertension). Sleep study results if you have obstructive sleep apnea.

1. Current medications. Full list, including supplements. Providers need to check for interactions and contraindications.

1. Family history. Specifically thyroid cancer or multiple endocrine neoplasia type 2, which are absolute contraindications.

1. Pregnancy status and plans. Semaglutide is contraindicated in pregnancy. Providers will ask about birth control and family planning.

The pattern we see consistently across telehealth consultations: patients who arrive with a written summary of prior weight loss attempts (dates, methods, outcomes) get prescribed at a rate 3 to 4 times higher than those who say "I've tried everything" without specifics. Specificity signals seriousness and provides the documentation the provider needs.

The three prescription pathways: traditional, telehealth, and compounded

The route you take to get semaglutide determines cost, timeline, insurance involvement, and which version of the medication you receive.

Pathway 1: Traditional in-person provider (primary care or endocrinology)

• Timeline: 1 to 3 visits over 1 to 6 months
• First visit: Assessment, documentation review, often a "try lifestyle modification and come back" instruction
• Second visit: If weight loss goals not met, discussion of medication options
• Prescription: Usually Wegovy if insurance is involved, sometimes Ozempic off-label if the provider has a clinical rationale
• Insurance: Provider submits prior authorization; approval takes 3 to 14 days
• Cost if covered: $25 to $50 copay per month typical
• Cost if denied: $900 to $1,350 per month for brand Wegovy; $800 to $950 for brand Ozempic
• Best for: Patients with insurance that covers GLP-1s for weight loss, patients with complex medical histories requiring in-person management

Pathway 2: Telehealth platform prescribing brand-name medication

• Timeline: 1 to 7 days from intake to prescription
• Process: Online intake form, asynchronous or synchronous video visit, prescription sent to pharmacy
• Prescription: Wegovy or Ozempic depending on platform and insurance
• Insurance: Some platforms work with insurance; most don't
• Cost: Same as pathway 1 if insurance involved; $900+ per month if cash pay
• Best for: Patients who meet clinical criteria but don't want to wait for multiple in-person visits

Pathway 3: Telehealth platform prescribing compounded semaglutide

• Timeline: 1 to 3 days from intake to shipment
• Process: Online intake, provider review, prescription sent to compounding pharmacy, medication shipped directly
• Prescription: Compounded semaglutide (not FDA-approved, prepared by state-licensed compounding pharmacy)
• Insurance: Not covered (compounded medications are excluded from insurance)
• Cost: $250 to $450 per month depending on dose and platform
• Best for: Patients who meet clinical criteria but don't have insurance coverage for brand-name GLP-1s
• Note: Only available while semaglutide remains on the FDA shortage list (as of April 2026, still listed)

FormBlends operates in pathway 3. We connect patients who meet clinical criteria with licensed providers who prescribe compounded semaglutide, which is shipped from a U.S.-based compounding pharmacy. The cost difference (roughly $500 to $900 per month less than brand-name) makes treatment accessible to patients without insurance coverage.

What most articles get wrong about insurance coverage

The most common error in published content about getting prescribed Ozempic for weight loss is the claim that "insurance doesn't cover Ozempic for weight loss." That's technically true but misleading in a way that causes patients to give up prematurely.

What's actually true:

• Insurance almost never covers Ozempic (the diabetes-indicated product) for weight loss when Wegovy (the obesity-indicated product) exists
• Insurance does cover Wegovy for weight loss if you meet FDA-approved criteria and the prior authorization is approved
• About 40% of commercial insurance plans cover Wegovy as of 2024 (up from 25% in 2022), according to a KFF analysis of employer-sponsored plans
• Medicare Part D does not cover any GLP-1 medication for weight loss (federal law prohibits Part D coverage of weight-loss drugs), but does cover Ozempic for diabetes
• Medicaid coverage varies by state; 12 states cover Wegovy for obesity as of April 2026

The second common error: assuming that meeting clinical criteria guarantees insurance approval. It doesn't. Prior authorization for Wegovy has a 60% to 70% initial approval rate across commercial plans. The most common denial reason is insufficient documentation of prior weight management attempts, not failure to meet BMI criteria (Nguyen et al., Obesity 2023).

The insurance coverage decision tree:

Your situation	Likely coverage path	Expected outcome
BMI 30+, commercial insurance, documented 6-month lifestyle program	Wegovy prior auth	65-75% approval rate
BMI 27-29.9, hypertension, commercial insurance, documented lifestyle attempts	Wegovy prior auth	50-60% approval rate
Type 2 diabetes, any BMI, any insurance	Ozempic for diabetes	85-95% approval rate
Medicare Part D, no diabetes	No coverage path	0% approval (prohibited by law)
Medicaid, coverage state	Wegovy prior auth	40-60% approval rate
Medicaid, non-coverage state	No coverage path	0% approval

If your insurance denies Wegovy, you have three options: appeal (success rate 20% to 30%), pay cash for brand-name ($900+ per month), or use a telehealth platform for compounded semaglutide ($250 to $450 per month).

The prior authorization process for Wegovy vs off-label Ozempic

Prior authorization is the insurance company's way of verifying that a medication is medically necessary before agreeing to cover it. For weight-loss medications, the process is more stringent than for most drug classes.

Wegovy prior authorization (typical requirements):

1. BMI documentation. Current BMI ≥ 30, or ≥ 27 with comorbidity, measured within the past 30 days.

1. Comorbidity documentation. If BMI is 27 to 29.9, lab results or diagnostic codes proving hypertension, dyslipidemia, prediabetes, sleep apnea, or cardiovascular disease.

1. Prior weight management attempts. Documentation of at least one of the following:

• Completion of a structured weight-loss program (commercial program like Weight Watchers, hospital-based program, or dietitian-supervised program) for 3 to 6 months
• Prescription weight-loss medication trial (phentermine, orlistat, naltrexone-bupropion, liraglutide) for 3 to 6 months
• Documented diet and exercise counseling visits with measured weights showing inadequate response

1. Contraindication screening. Attestation that the patient has no personal or family history of medullary thyroid carcinoma or MEN2, no history of pancreatitis, not pregnant or planning pregnancy.

1. Prescriber type. Some plans require the prescription to come from an endocrinologist or obesity medicine specialist rather than primary care.

The insurer reviews the submitted documentation and issues an approval, denial, or request for additional information within 3 to 14 days. If denied, the provider can submit an appeal with additional supporting documentation.

Ozempic off-label prior authorization:

Most insurance companies have a blanket policy denying coverage for off-label Ozempic for weight loss because Wegovy is the FDA-approved alternative. A few plans will cover it if:

• Wegovy is not available due to shortage (this was common in 2022-2023 but less so in 2026)
• The patient has tried and failed Wegovy due to side effects
• The patient has a documented medical reason why the 2.4 mg dose is contraindicated

Even with these justifications, approval rates are low (under 20%). The practical takeaway: if you want insurance coverage, pursue Wegovy authorization, not off-label Ozempic.

When providers say no: the four common denial patterns

Not every patient who wants a GLP-1 prescription gets one. Understanding why providers decline helps you either address the gap or pursue an alternative pathway.

Denial pattern 1: BMI doesn't meet threshold

If your BMI is under 27, you don't meet evidence-based criteria for pharmacotherapy. Providers who prescribe outside these bounds risk liability and insurance audits. A BMI of 25 to 26.9 is considered overweight but not obese, and the clinical trial data supporting GLP-1 use doesn't extend to this population.

What to do: If you're close to the threshold (BMI 26 to 26.9), document your weight and health metrics over 3 to 6 months. If you have a weight-related condition like prediabetes or hypertension, that strengthens the case. If your BMI is under 25, GLP-1 medications are not clinically appropriate for weight loss.

Denial pattern 2: Insufficient documentation of prior attempts

The most common denial. The provider asks, "What have you tried?" and the answer is vague ("I've tried dieting") or nonspecific ("I've tried everything"). Without documented evidence of failed attempts, the provider can't justify prescribing in the medical record.

What to do: Before your visit, write a timeline of specific weight-loss attempts with dates, methods, and outcomes. Example: "January-April 2024: followed 1,600-calorie diet with MyFitnessPal tracking, lost 6 pounds, regained 9 pounds by August. May-July 2025: attended Weight Watchers, lost 4 pounds, plateaued." Specificity turns a denial into an approval.

Denial pattern 3: Contraindication or high-risk medical history

Absolute contraindications (personal or family history of medullary thyroid carcinoma, MEN2 syndrome) result in automatic denial. Relative contraindications (history of pancreatitis, severe gastroparesis, active gallbladder disease, eating disorder) may result in denial or a recommendation to address the underlying condition first.

What to do: If the contraindication is absolute, GLP-1 medications are not safe for you. If it's relative, ask the provider what would need to change for them to reconsider. Example: if you have a history of pancreatitis that resolved 5 years ago, the provider may want a gastroenterology clearance letter.

Denial pattern 4: Provider discomfort with off-label prescribing or telehealth

Some providers are uncomfortable prescribing medications off-label for weight loss, especially if they practice in a large health system with restrictive formulary policies. Others are uncomfortable with telehealth prescribing for chronic medications.

What to do: Ask directly: "Are you comfortable prescribing semaglutide for weight loss, or would you prefer to refer me to a specialist?" If the answer is no, ask for a referral to endocrinology or obesity medicine. Alternatively, pursue a telehealth platform that specializes in weight management.

The cost comparison: brand Ozempic vs Wegovy vs compounded semaglutide

Cost is the deciding factor for most patients without insurance coverage. The price difference between brand-name and compounded semaglutide is large enough to determine whether treatment is financially sustainable.

Product	Typical monthly cost (cash pay)	Dose range	FDA approval status	Insurance coverage likelihood
Brand Ozempic	$900-$950	0.5 mg, 1 mg, 2 mg weekly	Approved for diabetes	High for diabetes, near-zero for weight loss
Brand Wegovy	$1,350-$1,450	2.4 mg weekly	Approved for obesity	40% of commercial plans, 0% Medicare Part D
Compounded semaglutide	$250-$450	0.25 mg to 2.4 mg weekly (customizable)	Not FDA-approved	Not covered by insurance
Compounded tirzepatide	$450-$650	2.5 mg to 15 mg weekly (customizable)	Not FDA-approved	Not covered by insurance

The cost of brand-name products reflects manufacturer pricing, not production cost. The active ingredient (semaglutide peptide) costs roughly $30 to $50 per month to produce at therapeutic doses. The remaining $900 to $1,400 covers research and development recoupment, marketing, distribution, and profit margin.

Compounded semaglutide is available at lower cost because compounding pharmacies don't carry the R&D or marketing costs. They prepare the medication in response to individual prescriptions under the FDA's compounding exemption, which allows state-licensed pharmacies to compound medications that are in shortage.

As of April 2026, semaglutide remains on the FDA drug shortage list, which permits compounding. If the shortage resolves and FDA removes semaglutide from the list, compounding pharmacies will no longer be able to prepare compounded versions, and patients will need to transition to brand-name products or discontinue treatment.

FormBlends pricing (April 2026): $299 per month for compounded semaglutide at maintenance dose (1.7 mg to 2.4 mg weekly), including provider consultation, medication, and shipping. Lower doses during titration are priced at $249 per month.

The FormBlends prescription decision tree

Use this decision tree to determine the fastest, most cost-effective path to semaglutide treatment based on your specific situation.

Start here: Do you have type 2 diabetes?

• Yes → See your primary care provider or endocrinologist for Ozempic prescribed for diabetes. Insurance approval rate is 85% to 95%. Weight loss is a documented secondary benefit. Cost with insurance: $25 to $50 per month.

• No → Continue to next question.

Is your BMI 30 or higher, or 27+ with a weight-related condition (hypertension, prediabetes, dyslipidemia, sleep apnea)?

• No → You don't meet clinical criteria for GLP-1 therapy for weight loss. Focus on lifestyle modification with medical supervision.

• Yes → Continue to next question.

Do you have commercial insurance that covers weight-loss medications?

• Not sure → Call your insurance and ask: "Does my plan cover Wegovy for obesity?" If yes, continue. If no, skip to the self-pay pathway.

• Yes → Continue to next question.

Can you document 3 to 6 months of failed diet and exercise attempts or a prior weight-loss program?

• No → Your provider will likely ask you to complete a supervised weight-loss program first. This takes 3 to 6 months but increases prior authorization approval rate to 65% to 75%.

• Yes → Schedule an appointment with your primary care provider or an obesity medicine specialist. Request a Wegovy prescription and prior authorization. Expected timeline: 2 to 4 weeks from visit to approval. If approved, cost: $25 to $50 per month. If denied, proceed to appeal or self-pay pathway.

Self-pay pathway: Can you afford $900+ per month for brand-name Wegovy?

• Yes → You can request a prescription from any licensed provider (in-person or telehealth) and fill it at a retail pharmacy. No prior authorization needed. GoodRx coupons sometimes reduce cost to $800 to $900.

• No → Compounded semaglutide through a telehealth platform is the most cost-effective option. Cost: $250 to $450 per month. Timeline: 1 to 3 days from intake to shipment. Requires meeting the same clinical criteria (BMI 30+ or 27+ with comorbidity).

FormBlends pathway: Complete online intake → provider reviews within 24 hours → if approved, prescription sent to compounding pharmacy → medication ships within 1 to 2 days → arrives at your door with injection supplies and instructions.

State-by-state telehealth prescribing restrictions

Telehealth prescribing regulations vary by state. Most states allow providers licensed in that state to prescribe controlled and non-controlled medications via telehealth after an appropriate patient evaluation. A few states have additional restrictions.

States with no additional telehealth restrictions for semaglutide (as of April 2026): Alabama, Alaska, Arizona, California, Colorado, Connecticut, Delaware, Florida, Georgia, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennessee, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin, Wyoming

States requiring initial in-person visit before telehealth prescribing of weight-loss medications: Arkansas (in-person visit required for controlled substances and certain chronic medications; semaglutide falls in a gray area; most telehealth platforms operate here but some don't)

States with compounding restrictions: Louisiana (additional compounding pharmacy licensing requirements; some platforms don't ship here)

States where FormBlends currently operates: All 50 states. We work with providers licensed in each state and ship from compounding pharmacies licensed to serve each state.

The regulatory landscape changes frequently. If you're using a telehealth platform, verify that they're licensed to operate in your state before starting intake.

When you should NOT pursue Ozempic or semaglutide for weight loss

Steelmanning the contrary view: there are situations where pursuing a GLP-1 prescription is not the right clinical decision, even if you meet BMI criteria.

You have an active eating disorder. Binge eating disorder, bulimia, anorexia, or orthorexia are contraindications. GLP-1 medications suppress appetite powerfully, which can worsen disordered eating patterns and mask the underlying psychological condition. The appropriate treatment is therapy (CBT or DBT) with a specialist in eating disorders, not appetite suppression.

You're pregnant, breastfeeding, or planning pregnancy within 2 months. Semaglutide is pregnancy category X (contraindicated). Animal studies show fetal harm. The medication must be discontinued at least 2 months before attempting conception to allow clearance. If you're breastfeeding, semaglutide passes into breast milk; safety data doesn't exist.

You have a personal or family history of medullary thyroid carcinoma or MEN2. This is an absolute contraindication. GLP-1 receptor agonists caused thyroid C-cell tumors in rodent studies. The FDA requires a black-box warning. If you or a first-degree relative has had medullary thyroid cancer, do not take semaglutide.

You've had pancreatitis in the past 6 months. GLP-1 medications carry a small but real pancreatitis risk (about 0.2% in clinical trials). If you've had recent pancreatitis, the risk of recurrence is elevated. Wait at least 6 to 12 months and get gastroenterology clearance.

Your BMI is under 27 and you have no weight-related comorbidities. The clinical trial data doesn't support GLP-1 use in this population. The risk-benefit ratio doesn't favor treatment. Focus on evidence-based lifestyle modification instead.

You're unwilling to make concurrent lifestyle changes. GLP-1 medications are not a replacement for diet and exercise. They're an adjunct. Patients who don't modify eating patterns or activity levels lose less weight and regain more after discontinuation. If you're looking for a medication-only solution, outcomes will disappoint.

You can't afford ongoing treatment. Semaglutide is not a short-term medication. The STEP-1 trial extension data shows that patients who discontinue treatment regain about two-thirds of lost weight within 12 months (Wilding et al., Diabetes Obesity and Metabolism 2022). If you can't sustain $250 to $1,400 per month indefinitely, starting treatment sets you up for weight regain and frustration.

A thoughtful provider will screen for these contraindications and have a frank conversation about whether starting treatment makes sense in your specific situation.

FAQ

Can I get Ozempic prescribed for weight loss without diabetes? Yes. Providers can prescribe Ozempic off-label for weight loss if you meet BMI criteria (30+ or 27+ with comorbidities) and have documented failed lifestyle modification attempts. However, insurance rarely covers off-label Ozempic for weight loss. Wegovy (same active ingredient, higher dose) is the FDA-approved option for weight loss and has better insurance coverage.

What BMI do I need to get prescribed Ozempic for weight loss? BMI of 30 or higher qualifies you automatically. BMI of 27 to 29.9 qualifies if you have at least one weight-related condition like hypertension, prediabetes, dyslipidemia, or obstructive sleep apnea. Below BMI 27, you don't meet evidence-based criteria for GLP-1 therapy.

Will my doctor prescribe Ozempic for weight loss? It depends on the provider. Many primary care providers and endocrinologists prescribe GLP-1 medications off-label for weight loss if you meet clinical criteria. Some are uncomfortable with off-label prescribing and will refer you to an obesity medicine specialist. Telehealth platforms specializing in weight management have higher prescription rates.

How much does Ozempic cost without insurance? Brand-name Ozempic costs $900 to $950 per month without insurance. GoodRx coupons sometimes reduce the price to $800 to $850. Compounded semaglutide through telehealth platforms costs $250 to $450 per month and is the most affordable option for patients without insurance coverage.

Does insurance cover Ozempic for weight loss? Almost never. Insurance companies deny coverage for off-label Ozempic for weight loss because Wegovy (FDA-approved for obesity) exists. About 40% of commercial insurance plans cover Wegovy if you meet criteria and prior authorization is approved. Medicare Part D does not cover any GLP-1 medication for weight loss by federal law.

What's the difference between Ozempic and Wegovy? Both contain semaglutide. Ozempic is approved for type 2 diabetes at doses of 0.5 mg, 1 mg, and 2 mg weekly. Wegovy is approved for chronic weight management at a dose of 2.4 mg weekly. The active ingredient and mechanism are identical; the indication and dose differ.

Can I get Ozempic through telehealth? Yes. Many telehealth platforms connect you with licensed providers who can prescribe Ozempic, Wegovy, or compounded semaglutide after an online consultation. The process typically takes 1 to 3 days from intake to prescription. FormBlends specializes in compounded semaglutide prescriptions through telehealth.

Do I need to try diet and exercise before getting prescribed Ozempic? Yes, in most cases. Clinical guidelines and insurance prior authorization requirements specify that patients should have documented attempts at lifestyle modification for 3 to 6 months before starting pharmacotherapy. Telehealth platforms are more flexible and often accept patient attestation of prior attempts.

What documentation do I need to get prescribed Ozempic for weight loss? You need current BMI measurement (within 30 days), documentation of prior weight-loss attempts (specific programs, dates, outcomes), and if your BMI is 27 to 29.9, proof of a weight-related comorbidity (lab results showing prediabetes, hypertension, or dyslipidemia). The more specific your documentation, the higher your approval likelihood.

Can I get Ozempic prescribed online? Yes. Telehealth platforms allow you to complete an online intake, have a video or asynchronous consultation with a licensed provider, and receive a prescription sent to a pharmacy. Some platforms prescribe brand-name Ozempic or Wegovy; others prescribe compounded semaglutide, which is less expensive.

How long does it take to get prescribed Ozempic? Through telehealth: 1 to 3 days from intake to prescription. Through traditional in-person providers: 1 to 6 months depending on whether the provider requires documented lifestyle modification attempts first. If insurance prior authorization is involved, add 3 to 14 days for approval.

What if my insurance denies Wegovy? You have three options: submit an appeal with additional documentation (20% to 30% success rate), pay cash for brand-name Wegovy ($1,350+ per month), or use a telehealth platform for compounded semaglutide ($250 to $450 per month). Most patients without insurance approval choose the compounded option.

Is compounded semaglutide the same as Ozempic? Compounded semaglutide contains the same active ingredient (semaglutide peptide) but is prepared by a compounding pharmacy rather than manufactured by Novo Nordisk. It's not FDA-approved and hasn't undergone the same testing as brand-name products. It's available at lower cost while semaglutide remains on the FDA shortage list.

Can I switch from Ozempic to compounded semaglutide? Yes. The active ingredient and dosing are equivalent. If you're currently on brand-name Ozempic and want to reduce cost, you can transition to compounded semaglutide at the same dose through a telehealth platform. Consult with the prescribing provider to ensure continuity of care.

What happens if I don't meet the BMI requirement? If your BMI is under 27, you don't meet clinical criteria for GLP-1 therapy for weight loss. Providers who prescribe outside evidence-based guidelines risk liability. Focus on lifestyle modification with medical supervision. If you have a weight-related condition, work with your provider to address that condition directly.

Sources

1. Sorli C et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN-1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes & Endocrinology. 2017.

1. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021.

1. Grunvald E et al. AGA Clinical Practice Guideline on pharmacological interventions for adults with obesity. Gastroenterology. 2022.

1. Nguyen A et al. Prior authorization and access to GLP-1 receptor agonists for obesity: a retrospective analysis of commercial insurance claims. Obesity. 2023.

1. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obesity and Metabolism. 2022.

1. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.

1. Rubino D et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA. 2021.

1. Kadouh H et al. GLP-1 receptor agonists and gastrointestinal adverse events: a systematic review. Diabetes Therapy. 2021.

1. Nauck MA et al. Cardiovascular actions and clinical outcomes with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Circulation. 2017.

1. Blonde L et al. American Association of Clinical Endocrinology Clinical Practice Guideline: developing a diabetes mellitus comprehensive care plan. Endocrine Practice. 2022.

1. Apovian CM et al. Pharmacological management of obesity: an Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology & Metabolism. 2015.

1. Kushner RF et al. Semaglutide 2.4 mg for the treatment of obesity: key elements of the STEP trials 1 to 5. Obesity. 2020.

1. KFF. Employer Health Benefits Survey 2024: Coverage of weight-loss medications. Kaiser Family Foundation. 2024.

1. FDA. Drug Shortages Database: Semaglutide injection. U.S. Food and Drug Administration. Updated April 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic and Wegovy are registered trademarks of Novo Nordisk. Weight Watchers is a registered trademark of WW International. GoodRx is a registered trademark of GoodRx Holdings. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.